TrialEuropean urology oncology2024

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.

Mamta Parikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.